Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication January 5, 2012
- Accepted for publication April 30, 2012
- Published online September 6, 2012.
Article Versions
- previous version (July 31, 2012 - 05:29).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Melpomeni Fani1,
- Friederike Braun1,
- Beatrice Waser2,
- Karin Beetschen2,
- Renzo Cescato2,
- Judit Erchegyi3,
- Jean E. Rivier3,
- Wolfgang A. Weber1,
- Helmut R. Maecke1 and
- Jean Claude Reubi2
- 1Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
- 2Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; and
- 3Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, California
- For correspondence or reprints contact: Jean Claude Reubi, Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland. E-mail: reubi{at}pathology.unibe.ch
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells
- Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
- Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Somatostatin Receptor Antagonists for Imaging and Therapy
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET
- In Vivo Radioimaging of Bradykinin Receptor B1, a Widely Overexpressed Molecule in Human Cancer
- Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study